SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BankrCoin ($BNKR) is attracting significant investor attention as a trending utility token within the Base ecosystem, driven by its integration with AI-powered trading infrastructure and agent-based financial tools. Community sentiment remains highly optimistic, with many active participants viewing current price action as a long-term accumulation phase for an asset they believe is deeply undervalued relative to its growing usage and ecosystem integration.

What is Chromia? Chromia is an open source public blockchain conceived of by Swedish company Chromaway AB. The Chroma token (CHR) was launched in May of 2019. The technology behind the Chromia blockchain is adapted from an earlier technology called ‘Postchain’, a solution provided by Chromaway AB for enterprise clients.&nbsp;  How does Chromia work? Chromia is a standalone Layer-1 blockchain and EVM compatible Layer-2 enhancement for Binance Smart Chain and Ethereum. It is designed to enhance existing dApps and allow for the creation of next-generation dApps by providing scalability, improved data handling, and customizable fee structures. The blockchain uses a unique architecture called relational blockchain, as well as a custom programming language called Rell.  Rell is designed to code and function very similarly to SQL, allowing developers to leverage the security and immutability of blockchain while storing and handling data with the efficiency of a relational database.&nbsp; Each dApp running on Chromia operates on its own sidechain which is rooted in the main blockchain. This allows each application to scale more efficiently and gives each application developer the freedom to choose from a variety of fee structures. For example, one application may require users to pay transaction fees in CHR (similar to how Ethereum or Bitcoin work), while another application could stake enough CHR to reserve computational power and allow their users to make unlimited transactions without paying any fees at all.&nbsp;  What applications have been built on Chromia? Chromia already has a wide variety of applications building upon their blockchain, using their chain as a decentralized storage layer, and using their Layer-2 enhancements. These applications range from DeFi options trading platform Hedget, to open world farming game My Neighbor Alice, to government land registry initiative LAC PropertyChain.&nbsp; One of the latest features in development is a new NFT standard called Chromia Originals, which will operate both as a native standard on Chromia’s chain as well as an enhancement layer for existing ERC-721 and BEP-721 tokens. Work on these Layer-2 enhancements are being developed in cooperation with My Neighbor Alice.  Who is behind Chromia? Chromia’s core team consists of industry veterans Or Perelman, Henrik Hjelte and Alex Mizrahi. All three have deep roots in the crypto space, going back to the early days of Bitcoin and Ethereum. For example, Alex published several early academic papers on Proof of Stake consensus and was also one of the key figures behind Colored Coins, one of the first projects to develop the idea of ‘tokens’ that would later be brought to prominence by Ethereum.  In summary, Chromia is a Layer-1 and Layer-2 blockchain solution under active development, with the goal of delivering enhanced features and data handling and storage capabilities to decentralized applications.

Chromia

Chromia is generating intense community buzz as traders track its technical setup, volume, and potential for a breakout. Investors are actively debating the token's long-term utility in the RWA and gaming sectors, with many focused on entry points while waiting for further ecosystem developments.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

crow with knife (CAW) is trending as the community rallies around its multichain expansion and deflationary tokenomics, often referring to themselves as a growing 'murder' of supporters. Investors are actively sharing bullish sentiment across social platforms and engagement channels, frequently highlighting the project's 'caw caw' brand identity and community-driven momentum.

Trio-Tech International engages in the provision of third-party semiconductor testing and burn-in services. It operates through the following segments: Semiconductor Back-End Solutions (SBS) and Industrial Electronics. The SBS segment is focused on the sale of burn-in and reliability test equipment used in the back-end manufacturing processes of semiconductors. Its equipment includes burn-in systems, burn-in boards, and related equipment that is used in the testing of structural integrity of integrated circuits. The Industrial Electronics segment consists of designing, manufacturing, and distributing a range of tests, processes, and other equipment used in the manufacturing processes of customers in various industries in the consumer and industrial market. The company was founded in 1958 and is headquartered in Los Angeles, CA.

Trio-Tech International

Trio-Tech International is trending as investors focus on its strong revenue growth and significant expansion in Malaysia, which are being linked to rising demand for AI GPU and automotive chip testing. Community discussions center on the stock's valuation gap compared to peers in the semiconductor testing sector, with many participants debating the potential for a significant re-rating if the company sustains its recent order momentum.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is trending as the community debates whether the recent pullback represents a healthy consolidation amid institutional accumulation or a deeper structural decline driven by rising treasury yields and geopolitical uncertainty. Market participants remain split, with many closely watching ETF flow patterns and key support levels to determine if the asset will initiate another leg up or face further downside pressure.

Evolution Metals & Technologies Corp. engages in developing a global supply chain for critical minerals and materials. It focuses on automotive, renewable energy, and military and defense sectors. The company is headquartered in West Palm Beach, FL.

Evolution Metals & Technologies Corp.

Evolution Metals & Technologies Corp. Common Stock

Evolution Metals & Technologies Corp. is attracting significant community attention due to its focus on domestic supply chain independence and a unique tech-integrated approach to the rare earth and critical minerals sector. Investors are actively discussing the stock's low-float volatility and potential for supply-chain-driven growth, though some traders remain cautious about heavy insider ownership and the typical market noise surrounding recent SPAC-related listings.

Pi Network is a social cryptocurrency and developer platform designed to make digital currency mining accessible to everyday people through mobile devices. The project aims to build a widely distributed currency that facilitates transactions for real-world goods and services rather than purely speculative trading. Its main value proposition is a mobile-first mining system that allows users to earn rewards on their phones without requiring specialized hardware, draining battery life, or using excessive data.  The network operates on the Stellar Consensus Protocol and a Federated Byzantine Agreement, which allows computers to reach agreement by trusting specific groups of other peers. Security is maintained through a global trust graph built from individual user groups called security circles where members vouch for each other. Users participate in four primary roles as pioneers, contributors, ambassadors, or nodes to ensure the network remains decentralized. This meritocratic distribution model rewards consistent engagement and network growth rather than financial wealth or technical power.  Founded by Dr. Nicolas Kokkalis and Dr. Chengdiao Fan, both of whom hold doctoral degrees from Stanford University, the project is managed by Social Chain Inc. The ecosystem includes a native wallet, a dedicated browser, and a platform for decentralized applications where the PI token is used for peer-to-peer exchange and transaction fees. Additionally, tokens can be used for purchasing goods in an internal marketplace, staking in a launchpad, or voluntary lockups that support market stability while boosting personal mining rates. The project has focused on organic community growth and does not list any external institutional investors in its documentation.

Pi Network

Pi Network continues to draw intense debate as the community remains divided between long-term holders awaiting further mainnet migration and vocal skeptics who view the project as an ad-driven scheme. Sentiment is largely fueled by speculation over future exchange listings and frustrations regarding the accessibility of earned tokens.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is facing heightened community anxiety as the token continues to struggle near multi-year lows, even as stakeholders look toward potential catalysts like a new spot ETF and broader institutional RWA tokenization trends. Traders are actively debating whether these depressed price levels represent a major long-term accumulation opportunity or a signal of deeper structural weakness in the altcoin sector.

Sprott Physical Silver Trust - Units

Sprott Physical Silver Trust ET

Sprott Physical Silver Trust is trending as investors grapple with massive volatility and persistent physical supply shortages, fueling community debate over the disconnect between paper markets and physical metal prices. Discussions are centered on institutional accumulation, potential market manipulation by major banks, and the ongoing structural deficit for silver in industrial applications.

Unleash Jugs

JUGS is capturing community attention as a new meme token that has seen significant early price momentum and high ownership concentration among top holders. Supporters are actively discussing the coin's low holder count and potential for volatility, drawing comparisons to other speculative crypto assets.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The study enrolled 20 high-risk patients with advanced, metastatic disease who had received one or more prior therapies.</li><li>The company said that the secondary endpoints included overall and progression-free survival.</li><li>Can-Fite announced exercise of certain outstanding warrants to purchase up to 795,869 ADS at a reduced price of $5 per share.&nbsp;</li></ul>Shares of Can-Fite BioPharma (CANF) surged more than 40% in pre-market trading on Wednesday after the company reported positive results from its Phase 2A open-label study of namodenoson in patients with advanced pancreatic ductal adenocarcinoma (PDAC) who had previously failed other treatments.The trial met its primary safety endpoint, showing that the drug was very well tolerated, with no new safety concerns observed. The study enrolled 20 high-risk patients with advanced, metastatic disease who had received one or more prior therapies.The company said that the secondary endpoints included overall and progression-free survival, with follow-up ongoing and one-third of patients still alive at data cut-off, as more mature results are expected to be presented at upcoming scientific meetings.Namodenoson is a selective A3 adenosine receptor agonist that has shown anti-tumor activity in preclinical models and is also being studied in advanced liver cancer. The drug has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer.<h2 class="st-heading-2">Exercising of Warrants for $4.0 Million Proceeds</h2>Can-Fite BioPharma also announced a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to 795,869 American Depositary Shares at a reduced price of $5 per share, down from $9.34. The transaction is expected to close around March 5, 2026.&nbsp;In connection with the cash exercise, the company will issue new unregistered warrants to purchase up to 1,591,738 ADSs at $5 per share, exercisable for 24 months.&nbsp;Can-Fite expects gross proceeds of about $4.0 million to support research, clinical trials, and general corporate purposes.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/CANF">CANF</a> on Stocktwits turned 'extremely bullish' from 'bullish' a day earlier, amid 'extremely high' message volumes.<img src="https://news.stocktwits-cdn.com/CANF_jpg_27fa5e9013.webp" alt="CANF.jpg">One user said the company is a "great buyout candidate."<stembedurl>https://stocktwits.com/Pindis7/message/646561779</stembedurl>Year-to-date, the stock gained 63%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did CANF Stock Soar 25% Today?

CANF company said its trial to study the treatment of patients with advanced pancreatic ductal adenocarcinoma met its primary endpoint.

Equity

The company said its trial to study the treatment of patients with advanced pancreatic ductal adenocarcinoma met its primary endpoint.

<ul class="summary-bullets"><li>The company said that the planned confirmation late-stage trial is designed to demonstrate the efficacy of Lacutamab in certain patients with Sézary syndrome and Mycosis fungoides.</li><li>The primary goal of the study is to gauge progression-free survival.&nbsp;</li><li>The FDA reviewed the protocol of the trial with no further comments, the company further noted.&nbsp; &nbsp;</li></ul>Shares of Innate Pharma SA (IPHA) soared 13% in the premarket session on Monday after the company said that the U.S. Food and Drug Administration had cleared a confirmatory late-stage trial of Lacutamab in cutaneous T-cell lymphomas to proceed.Cutaneous T-cell lymphoma (CTCL) is a rare type of non-Hodgkin lymphoma that affects the skin. Symptoms include patches, plaques, or tumors on the skin that can be itchy and may resemble eczema or psoriasis.<h2 class="st-heading-2">About the Late-Stage Confirmatory Trial</h2>The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20251109757297/en/Innate-Pharma-Announces-FDA-Clearance-to-Proceed-With-TELLOMAK-3-a-Confirmatory-Phase-3-Trial-of-Lacutamab-in-CTCL">said</a> that the planned confirmation late-stage trial is designed to demonstrate the efficacy of Lacutamab in patients with Sézary syndrome and Mycosis fungoides, who failed at least one prior line of systemic therapy. Both Sézary syndrome and Mycosis fungoides are types of cutaneous T-cell lymphomas.The primary goal of the study is to gauge progression-free survival or the length of time a patient lives with a disease, such as cancer, without it getting worse, which can include time when the cancer is stable or cured.The company now intends to initiate the confirmatory trial in the first half of 2026. The FDA reviewed the protocol of the trial with no further comments, the company further noted.In a mid-stage trial, Lacutamab demonstrated durable activity, a favorable safety profile, and improvements in patients’ quality of life.“...this milestone brings us one step closer to our next goal, submitting for accelerated approval in Sézary syndrome once the Phase 3 trial is underway,” CEO Jonathan Dickinson said.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/IPHA">IPHA stock</a> jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:623/63;" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAm8AAAA/CAYAAAC2Jy9WAAAQAElEQVR4AeydC1RU173/v4eHMwjCgIKMkchUY8TYNObRGNo8pP/4v0K5NWhesGJWRGkU41qJJr3tMlldqe1dbTVtY0CrYlbsxWiikoYr9porXpdX0TRqczVAfNzBiM4ElEEFZkYGuPt3hhlmhnkCDo/5zTp7zjl7//Zv7/OZM19+Z+9zhrAufjEBJsAEmAATYAJMgAkMGwJh4BcTYAJMgAkwgT4R4EpMgAkMBgEO3gaDOrfJBJgAE2ACTIAJMIE+EuDgrY/guNrQIsC9YQJMgAkwASYQKgQ4eAuVT5qPkwkwASbABJgAE3BHYNjleQ3ebt1qR3PzTTQ0NOHKlUZOzIDPAT4HBuUcIA0iLSJNGmiVJZ/km9pgnWOd53OAz4HBOgdIg0iLSJN86ZzH4I0cGAw3EBERgfj4WKjV4zBhQiInZsDnAJ8DQT0HSHtIg0iLSJNIm3wJm7/l5It8km9qg9oaVJ3jcyuo5xZ/1vw3faicA6Q9pEGkRaRJpE3edCzMXeG1a9fl7KSkBMTERCEyMgKSJMl5/MYEmAATCCYBSZJkDSItIk2itm0aRdt9TTYf5JN8s871lSTXYwJMoL8EJCkwnesVvFG0Fx4eBpVqDAds/f00hm997jkTGJIEJEmStYk0irSqr52kuuSDda6vBLkeE2ACt4uAJPnWOafgjeZZzeZbiIuLuV19Yr9MgAkwgX4TII0irSLNCtQZ1aG65CPQumzPBJiAPwTYZiAIkEaRVpFmufpzCt7a2kyIjh7NI26ulHifCTCBIUVAkiRZq0izAu0Y1WGdC5Qa2zMBJhBsApLkWeecgjeK7hSKyGD3j9tjAkyACQRMgLSKNMtbRXdlVIfquivjPCbABJjAUCJAWkWa5donp+DNYulARES4qw3vMwEmwASGHAHSKtKsQDtGdahuoPXYngkwASYQbAKkVaRZru06BW9UKEn8VClxGNjE3pgAExhoApLUd62SpL7XHejjYH9MgAkwAU8EJMm9VvUK3jw54HwmwASYABNgAkxgEAhwk0zAhQAHby5AeJcJMAEmwASYABNgAkOZwNAO3m7oobsxlPFx35hASBHggx3RBOpxtOwYLo3oY+SDYwIjg0D/g7dOPY7u2Iz16yltwNay02jq7COcxmMo3XvWXvn84TLsOnzBvn+7Nmr37sTRxtvlnf0yASYw3Ak0HNmJ4s37UeuobRcPYevGoakdli/LUVxe7YT9+vFd+OCg3inPeceAK3V6NDln8h4TYAJDkEC/gzfdf+3HGdUcvPLKEpEK8OT00VD01WuTAU1Gsx3TlKyleCVrsn3fvjGgGzfQdM0Mk2VAnbIzJjBsCHR1AUbxvbt5sw0Gw01cvdqMhoYm6PXXoNM1inQV3357DY2NBtC/lLp+vQUtLUa4e3x92Bx0gB3tMJsR0VWPM6d7Ktb+z0WYYB6S2hExVY24uouotXf3Br762oAkTbI9hzeYQCgRGGk619cwy/6Zm271BFtAOFLunozo7tLW84ewY/NmFBdvxlYxotZK+TS6Vv4FzuzdhuL33sMf6GrWKAoo/7MLsFz+bxR3X83S1W7pEeuQGG2XHzmNT94XI3x/2ozSo/W4dHgXthYLHxvL8aXsXPjpNODLMuF7o2h30y4cvSzyxEKja5X/OCL3Z71c33oFSvknDELYyoS96KMw5YUJjHgC7e0W3LjRKgdkt27dwvXrN3HzZqsI4kxyUEaPpnd2doIEr0u8dXR0gurQr323thpF3RbQmoI5g/j+UPBHdiMZXERsLJrOnbYeYudZ1DbEImm0dVd+b72Ayh1bhX4JLSnZh9puTdId2YVNQgOLN27FjsP1oOtEd3lN/9iHD0gv39uA9dsOQWcb5bt8TNatYtI0Oe20zhR4aE/uS9RUaOLqoa2T90R0fhba6xOhSRX7No2kPhVvQ3lNm8h0WUiP/+0YGrqzSX9LB0iLu10O6oobDw0CpFkjVef6HbxpHn0c6m/KRRD2CSpPN8rCJJ8WTcewa78BablLsGzZInz/1iFUfi1KLGaY675G0715WLZ8OeYmXcDxkzeAxFnIe3QicMcPsezlZ5GeCNDVrtncISpZt+sumvHYi2KE74XpsBwvx/Exc7Bo2XJkp+hx4nNrkFe7dxdOxM0RPkS7T6lx7sAxXBcezMZG1F6Mx9z87vonTslXpdOysnFPTCzueUrYZ00VlrwwgZFLgIKypqYbctDW0tLWHZC1Q6EYFfBBjxo1ChTMUeBGARyN1rWKwE7EegH7GhYVkiZDY/gaJ+hi82uhYXdMREK7recGHN1diaa052TtKZhlQWUl3QJSjeNfAA+/LPTl5UVYMGsiIuAuD1CoZ2Ke0Kdly5fiybhq7K8SuohGVP6tGmPnUP0lmJOiQMr/e1boo6f2bP2JxT2TR+PS2Xo5w3z6AppSJ2Oa2KvduwMnhHYuWyZ8vjgTrQfKcNR1rpR0Wow2WtXXqr8DpcWiC7wwgdtKIBR0rt/BG6KnIrtgKV58LBFNx3ZiffdImvn8RdwQV6qWr0/hxMn/gXmUAo2XraNdGD0Rd6WEg15xY6JFkObmyo8KXVJ0shBL6nFCLKKhxl33xcoW0VEKoItk5iK0l8ORoNSJNkW7lyxQtOhRB+srKXU64mz1SZys2fzOBAaJQPCa7ejoEFOiN+TpUJPJcbQccgDWl+AtjL5LDodAo3M0pUpBHAV0DkUjZFONGZPbcO6rNtSeNSAlTVxs2o7MeEGMbMUirkMEdydP4UtjBJQNOuiQCs0dBhzfdQhndGZEREK83OUB0eMT0VF3CpV7y/GPqxQwkS6SrimgGCOqiSU83IwbTeLz89ieMOpe4tJSobh0QfQBqP2mCalT6eKUNDIaqd/rnj6N/i7um3QD2vPCZ3c9f1b91WJ/2mAbJhAogVDSORf5DRSVzV4ETHf/AAuWLEJ69FmcOG2GSUzL2Erltfq7+P7d8fLm7Xszw9Lu6D0Wd82aiRTHLN5mAiFGgKZDv/22SUyJuv8DTVMLkZERAVGJiAgX06s0Adi7mk1A6d45ugLubTF8c9T3TYb57H6cuT4JMyY5HIfZ0jPrQNlhyfjerLuRgNH43gIx4vZgNLT7t6G4rBpmt3liJO3ftmLfeQXuenQOHtdEkxeRkvHwTAW+3L0Tn5TtxMGGqch4UCEibk/tiSq2JWGy0L56aJtO45w+FXfdTQWkkeFQRtJ2T7K0uz83eiwC3aJ2HOuwFjvS4O2BJxBqOicHb33H2Ibaw1/gklPABDEFo0DcRDUUbRYk3DcTD9wvkljPuEMBn69OnxZeDCZhQmIbWiPutrYptztJCKiXKnKRBR39ald2wm9MYEgRoMCJHjKgBxF8dYwCrvBw/+VAIaZZacrUm99bt9rl6VmaSvVmN6zKEqZD016PVs29UDt2XDURExStsCQIrSPdoZSWDAU6xAVlOBK+8yCyX5yFpG8u4JzbvHpcMSTjgTnTkRKrQKvRFkzdwJfVHXhg/jzM/tE8LFr4ONT0MXlsz7FTyUjTdEBbeQENKdYpU2CS0EgDtGfbrIadF6HVKTBhonUWw5op3seLsLPFgAZZF9vQcLVVZAayUDt90eJA2mBbJgCEqs6RDPTj8x+NpDE67Nu4wXqT7nsf4MSoHyDje8LlpAxk32PAvuJtKBVXjPIj9ddEvrdl6lRoGg5h/UZxBUr3x3mzdVumwAPZcxD75Qco3vYJdm3bik17z8Img26rQAjcdyJwZs9mFO84xo/Ju4fEucOMAAVOV68a5Hva/Om62RzYfW+RkZGyaPryTQ8x0FRqc/NNX6bDpDwejz23EAtmxbv0dyKezJqOpr9twNbt5Sgt2YzSYwag8RR2vb8VH+yivGNovfchzHCXh4nQJOrxWclOlH5Qihrj6G7/sUhJasXx7UJHRSp+fyfKD19Aq7B32x6cX+rJE9F6SYcJQlutJY4aWYqtxfvRdE8mnpRHEeMRF12PE4f1QNhUzLhTh0p6qGFjGRqiE6zV3b+7yXVsx18tduOGs5iAFwKhrHP9DN4gRtayUfDKUuTnPosXf7oUyxbMtI90qX/wLJYtexY/pitGsU4fKz4F9eNYlC+uHsUmLeqMhViU0X3/RdR0zFu+FAUvLcJcMcTvWOa4DXwXC16dB4oRe/mge/CWCB/zMzD3+UUoyJ4qrn4hpi6WY4Gtgmv92QvxasFCFDw3y9538suJCQxHAnS/GU1ZdnZ2+d19s/mWGDH3/6GFri55SMZv/21tJvlnRrqG6dMMTvqjiEW0PO2YjIz8hciwDcHdMQt5Ly9F3o8fx4KXliAvXQR4iQ/iuYJFyJv7OOYtXIIXZycD7vIQjweeW4KCp+diwQt5yF6QZ9XFzrP4x+WJmEcPF7wsyp+ZBeXZIziuE+jdtSeynRZxEV3w6lLMS3PItWtkNvKE37wfiD7JxSIAXbwUC+V9BWY8JfR84bPIL8gTgemz1v4IOycWrlrqqOf2djKctFi44IUJ9JtAqOtcWL8JdjtQxNoErTvDtgpTIE5MA8DvV7j4I4J+vyKiPfTHk2eFAoHd9ePJEecPGgFuWP75DnryM1AU9LCBQhGJuLgYxMfHYtw4FZKSEqBWj5MTbVMelalUY0DTrIG2QQEi/bTIcA3g/D1e0kJFmLO1Oz1yl9errrlVTKG2oamZHlwAOm7o0NARjyRVj/9edXqKvG5R+679RFg4Ihz63lffjg1TO9Zg1zGXt5lA3wnQrRihrnMOX9O+g+SaTIAJDD4BGt2iKcpAejJ6tFIO1ChICwsLQ3R0FKKiFBg1KhL0UIIkSZAkSd6mPCqjOrGxMUhMjEdMzGiEh4f53SRNc1AA53eFUDeMmokF8yeh4VAFPikrx74vI8S0bTZmRIU6GD7+UCVwO3WONG+46Jz/qhuqZwofNxMYBgTopt1AAjd64GD8+ASoxCgaiVVfDjEyMgKxsdEYP36sWMfIQR78eFEARz+c6YcpmwgCEeNnYu5T2ZhH6Z8eREqsyOSFCYQgAda5ng+dg7ceFrzFBIYlAZqGbGq6Dlr7OoAwMboWHz8GY8fGiRGzcF/mfpfHxESJadZ4UFDoTyX6gWCaRvXHNvRs+IiZABNwJUD6xjrXQyWsZ5O3mAATGI4EaMSNrkh99T0iIlye6oyKUvoy7VN5eHi4HBTS1Ks/DgyGm6B77fyxZRsmwARCmwDrnPPnz8GbMw/ecyDAm0OfQGdnJ0ymWz47SlOjdI9aePjt/8rTQw/+BHDUd6PR5LPvbMAEmEBoEyCtYJ1zPgduv5I7t8d7TIAJDCABGnEbPz5BftDAk1sK3GiaVJIkTyYDnu8rgIuIiBCjdCq0Se2ov351wNtnh0yACQw6gQHrAOtcb5QcvPVmwjlMYFgQoH9rRb/nRomeAqWf86BAzbHzNNKWkBDn98MEjnX7u00BnOs9cGFhkvxzJDHxo7H+eDke3/gGfnNwZ3+b4vpMgAmMUAKs1vaDogAAEABJREFUc+4/2P4Hb6Zm6PV6l9QMk8V9g0MztxKrUtRQv1YZWPdcjr25JbDqqCtClmg3a4NWrqjdkAV1ShaK6mjXhIoVasSnrEKVV5Z97Ds1wWlYE7D92yubuNH/9qPfYUtIiLU/jED7FDAN1oFSX+heO2qfplITkxLwN+1JZGz6FxRX/TvMlnb8x9cnoW3Sk8ntSQPh1eW7btW80NK5ZpMjSBOaSfdtmeeLkB4fj6z3/fgcXXTP0StvMwFXAqxzrkSs+/0P3j4rhFotAh+nlN4dgFgbcfdesVCCtLDCXdEg5JmgqxcB6FUndfLdD5djjx8jjillPkpqfVeVLSwmaEW7WlvQ16KFvl7bE/iK7ohFNvX81se+e3bIJcOAAE0jmExmp54ajWY0NDShvb0DiYkqMS0ZJ/9em5NRkHckSUKCGPlLSoqHtrUBT/1lDV7fW4KGluv2nnShCxuODRUtsHfLecPlu27VvNDSucLPHJFUopA0f0VlT6bJt1rJxq66J2fyGxPoTYB1rjcTW07/g7duTznbdNDpbOkoClO7C9yu9CJYclswLDPtx356CzKv7sHiZSXQ9z6SAHOUyNykg/HSWjwSEWBVH+a//OUv8cwzz/iw4uKhTIB+qNJd/+hxehqBa2w0BBy41dfX47HHHpOnWMPDw/Hzn/9cBILtcjMtLS144okn5DJJEhcpItE+5csGXt5o5G3LF/uRIwK3M3p5WLmXdXnNcbS1OwejvYyGQIb9uy5rXWjpnFf8Uwpx1GjE3peSvZr1tZA1q6/khne9YOucjZbFYsHSpUtlvfvtb39ry/a6DrbODVjwplQlIznZllRQWqqw+iE11HOKIE8Kiv1VaWrc/8Z2/DFzJpYfBPBhnpgmVMM6bWid/lteXoN1j0YJaNOx7rywuVqBVTNpn/5gCNvNNSKTFqv94s2VWJepFvaiXJ0lRr302L6wez8yHescR8E8+iJ/tqRFUYbod45DANayB4tpenOz3mbktLYf+4z5yJktim42wyhWgLWP1uOjDOFb9FWd2c2EsrykytdEP8S0qfXathlVb6UjSvzRlCRxrK4jfJZTKBK+JUmUuR63SxskhNOnT+cAzoXLcNr1JGq2YyAhkSTJtutzTWL1+uuv4/Llyzh27Bj++te/4s9//jNKSkrkuq2trbh06RJyc3Px8ccfy4nOI6VSKZf7epuRPMmrCU2f/ue5U15thkKh/bsua11o6ZxX/q5ToZYalOR067A4D+OFfqpF6tFC4a1RaHua1K3di1HRLPI8LHSusWZ5gDOCs4OtczaUBw8exF/+8hcoFApbll/rYOrcgAVv2sN7sOdja6qsNQHKR7D67SyYPluO5R82Q79hpQikpqNwRQ7+/6urkUMXaLPyUfROEVbOVgswJjEap0fRP09HkXoNSj8qRV7qKREAZmFdSx52n9ahems6jhakY9UxiJfVvqRgPioeXIfdv8uBSl+BxWkarFGuxu5thZhpqcIqESyK3gAiuFn9UJYHX8KdfdFg/lMa6MtKsLvemmkqL0FJvQaZc6nT1jzHd9uxF72WiVX7VMh5LQ8a2cDaR/u0qMgzXdJDf0nukdjzvpiuCtt6HWTr8yXI/1UV0t+tFiOc1di7IgMax+58uBZ7iIPtuH2M/rEYemc/lEvpPxTQo/Pe+hgTE+2tuFfZtWvX8PnnnyM/Px8PP/wwsrKy8JOf/AQ7duwAja5RexTg3XvvvViwYIGcnnjiCdBTo72cucn4Yeo9mJGc6qakJ+vfaz7v2RmiW7bvOmldqOocHfuejyutF+W2z8nifAtIjdD+xWXT8d45I4zn3sP99XrEz13TrfXWSjW/X4fmFbu7tbsE89+qshZ4eGfN8gBmhGYPhs4RyoaGBrz66quyxo0bN46y/E7B1LkBC96qfj8f85+xpuXlOvlglXPXouR5JSp+kYHMN6qQ9rstyJ+oRNqTmbifmGgykPN0DjKmKWV7+W3Wezj60UrkPj0TyZ8V4dd1QO7ba5Au7OPnFiI/tRkVh+WxPNkcL5TiwNu5yHl9DVZNE1kz1mDvpkLkvLASeTPEvlZM5YoV/PFFdiIlv7QcOahCaRmNtJlEUFoBzM7H/Imi0M1StbkQha8VYs2GKjRHiGOp18LLRST689LVaGGISUPm64XIcPjn1HYOL6zFqmzRQmMzjGLlbWEx9EZn6Jb5+r2j8PAwccUYGdABhItpUhpFu3Lliv0/NSQlJUGr1eLmzZugf0RPqbq6GgUFBfjVr36Fq1evBtTGs/c+6tX+yMVqdHZ1ebUZ7MKQ1jkHjZ//zDp4C7W0dUKjZ2Qic4oSyiliLbS4RlzSOmp92u8OYMvSHKHdq1GYDJiaDT4/XtYsn4hGjMFg6BzddrJ+/XpZ75YtW2Z/8CsQqMHSubBAOuXNNvfTLln06eCrX7eOOwFiFGpFIVR1p3DKko/3XrXlw/PrLg3E91gu1545Kq+354rpQ7o5Vv0jrBPBnJzZ602IRESvTHtGQL5iclG4VImqTaXQWiqxtwzIeD7L3i+70+6NXLrf75IIEo1dqH47HnveyMPaM92FA7WashK7N+XAsDkL08dIUOeUoMbtU6hKqFTg1wgm0N7u9oO3H/Ho0Ur7tr8bY8eOxZNPPokNGzbg6aefxhNiVO0Pf/iDvbrZbMaECRMQFxeHO++8E2vXrpVt6CoVfr5+nPZ9hEueJcfYfgsXrlkv/Px0GXSzkNY5B43v6tqLXC/07380AzhTgqKDWmgPFqFE6GHO7HQPNVSIFxfnHgo5O0QJDIbOfS5mHzZu3Ai6zy0lJaVP5IOlc56VtE/ddq2kR8kv1sE0OwNplhL82p/HyB1caKbNFHtKFFb2BIY9waEoCmAJ1FdGbj6UQnz2vF+BPchE/vPJfrWWJkRLKSYUxICF3d5gGJhxuLQlu6EzGlH9US6iyhYj6+0aext92aCrWBpJ+eijj/pSnesMEoH29navLSsUo7yWuyuUJAnr1q3Dp59+Kgdpb7zxBt588015WjQsLAyTJ0+Wp1XfffddrF69GsXFxfjqq69w4sQJd+7c5sUpozF9/J1uy2yZX3170bY5jNahp3O+PpzkpwuRozRgz7J0pC87hfSt1Sh9PvCLCtd2WLNciYzc/WDrnFH8bf3Zz34mAy0rK8OqVatAPwlE9/ja7v2FH69g6dyABW+O94LQPRGn6oHmD/Ox+GAa1mw6gJJXVKgsyMd2WxxD3+OPS7G9To/mFg9EZuchX2VCUcFi7DmjFyC1OOV6r4WHqr2y/fFlaobtZ4vww0KsTK3B6hUlMGXnISeml0d7hqm5u2/7irD4pSKYxKRr1mwqjke8OE59eSkq67SofCsPq85QvksSwZ3j7+IZmk0uBmK3tgSrfl8JvUmJNAqGRZbR4sZO5PuzsAj6Q2no2dD/Au3s9D61GBnpZQjayyHR1GlWVhYoQMvIyMCRI0cwbdo0ebSNpkzpwslWPSoqSt6k++DkDT/ffN3QW9t4yU9Pg2MWyjoXCHHt5tXYc98q7P27DrqaA9jyUhqEFAbiopftgGtWrxY4Y6gQGAydi4yMlKdLSdsOHDiAgwcP4tatW6itrZUvVANhEwydCwukQ95sHe8FoXvf1v73HhQuqoDyhbUonAI88nYJcpUVyFu4Hc3QIP+tfCSbtiNPo4bmrSq4fcVkYkvVFmS2lGD+d2nq9Du4f0URqurcWnvP9OorA3kvqYCP81C4z+YmDctfewQmkwk5z+d4FZ49C7v7lrkcu1X52H2uFLlysPcIVv7uEeDMOvxI8x3kfZGPtS+g5zUlB/kPAjX/mgd6slbzVD5moga/fmGdeO8xo63m5mbUvPMjqMWUqZS4GBXTVqL0DRqZpNLAUmpqKqqrq8EjboFxGwrWnZ2dXrsREREOSZK82ngq3L9/P+gK8+LFi/jNb34DErCf/vSnUCgUeOedd+RH58+dO4eamhr88Y9/xB133IEZM2Z4cuc2f1piitt8W+bV1hu2zSG5DmWdC+QD0czNQ9qxVaBbPCRJks9JSf41gEC89NiyZvWwCIWtwdA5miY9fPgwvvnmGznRrALdIkIzEKR/gXAPhs71P3jLLrXf60ZX5rZU+lwOSo1dMG7LtAY+Kut+16e5EGESVNlbxBSgAbpGIwzviABHTE2WdnWhS9jD8TUtH3t1wk+juIJrNKJLtxu5qWSQCWd7DVae7kLX6ZXQULF4d94XmR59KZG51QBjowEldLO/MO1ZcjA/28M1o5tjN/x9C3Km9NhrXjmKrpviOA1G6CrysXKbSx//boRBdxQr6WGLKStx0ihsq1YiTXQgk2y7SgUZQDVrZQ8H4aurZm33AwuZLhwAuZ6dg3DkstTV1XHg5sJkEHcDatqXqNEUZ0AOu43pe3v+/Hk5QKM/lHTPx5/+9CdkZ2dDkiTQPXCHDh3C1KlTQT/ZQFejmzdvhkaj6fbg3yoxOs6rYZOxxWv5oBW6+a4Ts1DSudJsR/ouuiO0q1rot/V+ZxMq3lkL0+sHoNPprOn0Wjyir8C6ci3gZEs+NVbtdtV+KupOdaxZ3SRCYzUYOjeQZIOhc/0P3vpzxEoVkscp/fKgHJfst60vh558KcepoIwQtc9Xouj385G+ogqan6+GdRRN5Pd1iRHHqfJ0nEqokkW76H4pvdkCct89+ur2wasRS6DTx5RpWJjUp2OXJAn0dBX9ntu3334LWtO+JFn9PfTQQ/KIm8FgAJXTH+W5c+cG3FbC6DFe6xjabnotH5aF9J0ep/Sr6/L3209bXw49+bptOmfv0ClUfNgMg74ZQtyQLPQNNSfFbIIK6TPUdiveYAKeCAyWzjn2h/6LykUxC2G7D86xzNd2MHSuJ3jz1ZsQKtd+tg5r3q2B5s29OPl236YmQwgXH2oQCURFKTBhQqLHRP+Kqj/dofs+6CdCaO3Oj0qlApXT/XHuyn3lfT9lKv73Z1s9prKFb/pyweUDROD26dwjWFMhZkDK50MdJYmR2yhofqFH/p4abJmrHKDes5uRTGCwda6/bIOhcxy8ufmUNEv3QnepGgfezoQqwo0BZzEBJsAEhjmBgdY5Rxyq2Wtx0tBlv6XGeO4A1j6V7GjC20yACfSDQFg/6nJVJsAEmAATYAJMgAkwgSAT4OAtyMC5udtNgP0zASbABJgAExjZBDh4G9mfLx8dE2ACTIAJMAEm4C+BYWLXK3ijx9+HSd+5m0yACYQwgf5oVX/qhjByPnQmwASCTMCTVjkFb/QDnxZLR5C7xs0xASbABAInQFpFmhVoTapDdQOtF2R7bo4JMAEmANIq0ixXFE7B26hRkTCb211teJ8JMAEmMOQIkFaRZgXaMapDdQOtx/ZMgAkwgWATIK0izXJt1yl4Gz1aidbWNvnxbldD3g9RAnzYTGAIEqCpBNIq0qxAu0d1qC75CLQu2zMBJsAEgkWANIq0ijTLtU2n4I2iO4ViFK5fb5vjhb0AAAGiSURBVHG1430mwASYwJAhQBpFWkWaFWinqA7VJR+B1mV7JsAEAiPA1n0nQBpFWkWa5erFKXijQpVqDDo6OtHcfJNH4AgIJybABIYMAboSJW0ijSKt6mvHqC75IF/ks69+uB4TYAJMYKAJkCaRNpFGkVa5898reCOjsWOt/zy6oaEJLS1GtLdbOJAjMJyYABMIOgESMtIg0iLSJOqATaNo27/U28rmg3ySb2qD2uptyTlMgAkwgdtLgLSHNIi0iDSJWrNpFG27JrfBGxlRtBcfHwuLxQKD4QZ0uqu4cqWREzPgc4DPgaCeA6Q9pEGkRaRJpE2kUQORyBf5JN/UBrXFOsc6z+cAnwPBPgdIe0iDSItIk0ibvGmcx+CNKtE8KzlISkrw+I+wvf2TbC5L7MWNmTATPgcCPwdIg0iLSJNImwYykU/yTW3wZxP4Z8PMmBmfAwNzDpAGkRaRJvnSOK/Bm6/KXM4EmAATYAJMgAkEjQA3xARkAhy8yRj4jQkwASbABJgAE2ACw4MAB2/D43PiXjKBoUWAe8MEmAATYAKDRuD/AAAA//9bFwlaAAAABklEQVQDANkHaRvWK5L6AAAAAElFTkSuQmCC" width="623" height="63" alt="IPHA's Sentiment Meter and Message Volume as of 6:25 a.m. ET on Nov. 10, 2025 | Source: Stocktwits"><figcaption>IPHA's Sentiment Meter and Message Volume as of 6:25 a.m. ET on Nov. 10, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user recommended buying the stock under $3.<stembedurl>https://stocktwits.com/Iiii1ii/message/635561240</stembedurl>Another cheered the news as significant and positive.<stembedurl>https://stocktwits.com/StockNews_Live/message/635557846</stembedurl>IPHA stock is down by 4% this year and over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/us-lawmakers-reportedly-urge-ceo-to-end-union-busting-practices/cLPcLtxREcz">Starbucks Faces Political Heat: US Lawmakers Reportedly Urge CEO To End 'Union Busting’ Practices</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

IPHA Stock Soars Pre-Market After FDA Clears Late-Stage Trial For Lacutamab In Rare Skin Cancers

Shares of Innate Pharma SA (IPHA) soared 13% in the premarket session on Monday after the company said that the U.S. Food and Drug Administration had cleared a confirmatory late-stage trial of Lacutamab in cutaneous T-cell lymphomas to proceed.

The company now intends to initiate the confirmatory trial in the first half of 2026.


Shares of Caribou Biosciences, Inc. (CRBU) jumped 52% in the pre-market session on Monday after the company announced positive data from early-stage trials of two of its CAR-T cell therapies.While one of the therapies was evaluated for the treatment of multiple myeloma, a blood cancer of plasma cells, the other was assessed in B-cell non-Hodgkin lymphoma (NHL), a cancer that originates in B lymphocytes, a type of white blood cell that fights infection.<h2 class="st-heading-2">Study In Multiple Myeloma</h2>The company said that the first clinical data for its CB-011 <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/03/3179047/0/en/Caribou-Biosciences-Announces-Positive-Data-from-CaMMouflage-Phase-1-Trial-of-CB-011-in-Multiple-Myeloma.html">highlights</a> its potential as a best-in-class allogeneic CAR-T cell therapy for relapsed or refractory multiple myeloma.The company now expects to advance the program into the dose expansion phase by the end of the year. In the dose escalation portion of the trial, CB-011 had a manageable safety profile across all dose levels, the company noted. The portion of the trial evaluated the safety and efficacy of CB-011 in 48 patients at multiple dose levels and following two different chemotherapy treatments.<h2 class="st-heading-2">Study In B-cell non-Hodgkin lymphoma</h2>Meanwhile, data from an early-stage trial of vispacabtagene regedleucel (Vispa-cel) demonstrated the efficacy and durability of the cell therapy in patients with relapsed or refractory B-cell non-Hodgkin lymphoma, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/03/3179104/0/en/Caribou-Biosciences-Announces-Positive-Data-from-ANTLER-Phase-1-Trial-Demonstrating-Efficacy-and-Durability-of-Vispa-cel-CB-010-an-Allogeneic-CAR-T-Cell-Therapy-on-Par-with-Autolog.html">said</a>. Vispa-cel was generally well-tolerated, allowing for administration in the outpatient setting, the company added.“We believe that with these results, Caribou has achieved what the field has long sought — strong evidence that an allogeneic CAR-T cell therapy can be on par with the efficacy and durability of autologous treatments and broaden access with a safety profile that allows for outpatient use,” said CEO Rachel Haurwitz.Allogeneic CAR-T cell therapy is a type of "off-the-shelf" cancer treatment that uses T-cells from a healthy donor, rather than the patient's own cells, allowing immediate availability. Autologous therapy, however, uses a patient's own cells or tissues, which are collected, processed outside the body, and then reintroduced to the same individual.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CRBU">CRBU stock</a> stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.CRBU stock is up 52% this year and approximately 3% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ford-sales-in-us-rise-1.6-percent-in-october/cL2NX8OR3CR">Ford Sales In US Rise 1.6% In October On Continued Truck Demand</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Caribou Biosciences Stock Soars Pre-market On Positive Early Trial Data For  Cancer Treatments

The company announced positive data from trials of CB-011 and Vispa-cel in relapsed or refractory multiple myeloma and B-cell non-Hodgkin lymphoma, respectively. 

Vor Bio (VOR) announced on Wednesday that its collaborator, RemeGen Co., achieved the primary goal in a late-stage study in China evaluating Telitacicept in adults with primary Sjögren's disease.Shares of <a href="https://stocktwits.com/symbol/VOR">VOR</a> jumped 19% in morning trade at the time of writing. On Stocktwits, retail sentiment around Vor Bio jumped from ‘bearish’ to ‘extremely bullish’ over the past 24 hours, while message volume rose from ‘extremely low’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:628/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_13_at_10_23_25_AM_png_ff26de0d0d.webp" alt="VOR's Sentiment Meter and Message Volume as of 10:23 a.m. ET on Aug. 13, 2025 | Source: Stocktwits" width="628" height="64"><figcaption>VOR's Sentiment Meter and Message Volume as of 10:23 a.m. ET on Aug. 13, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism about Vor, highlighting its ongoing trials and funding availability.<stembedurl>https://stocktwits.com/StockGuru95/message/624945818</stembedurl>Another said they are eyeing a breakout for the stock.<stembedurl>https://stocktwits.com/StockGuru95/message/624929413</stembedurl>The late-stage clinical study in China achieved the primary endpoint of improving disease activity measured by a reduction in EULAR Sjögren's syndrome disease activity index (ESSDAI), compared to placebo, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.vorbio.com/news-releases/news-release-details/telitacicept-achieved-primary-endpoint-phase-3-clinical-study">said</a>. Telitacicept also demonstrated a favorable safety profile in the study, it added.RemeGen now plans to submit a Biologics License Application (BLA) to the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China for primary Sjögren’s disease. If approved, primary Sjögren’s disease will become Telitacicept’s fourth approved indication in China after systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG), Vor Bio noted.Sjögren’s disease is a chronic autoimmune condition in which overactive B cells drive inflammation, damaging moisture-producing glands and, in many cases, other organs. Symptoms include dry eyes and dry mouth, alongside fatigue, pain, and systemic complications affecting the skin, lungs, kidneys, and nervous system.“Sjögren’s represents a significant global expansion opportunity for Vor beyond myasthenia gravis, further extending the reach and impact of our portfolio,” said Vor Bio CEO Jean-Paul Kress.Vor Bio and Remegen entered into an exclusive license agreement granting Vor Bio the global rights to develop and commercialize Telitacicept, excluding China, Hong Kong, Macau, and Taiwan, in June. On Wednesday, the company said that it is evaluating the timing of a global late-stage study of the drug in primary Sjögren's disease.VOR stock is up by 78% this year and by 138% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/virtuals-turns-agents-into-a-team/chrCLP7Rd9L">Virtuals Turns Agents Into A Team</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Vor Bio Stock Jumped 19% Today And Retail Investors Are Eyeing A Breakout Rally: Here’s What’s Happening

A late-stage clinical study in China conducted by Vor Bio’s collaborator RemeGen Co., which is evaluating Telitacicept in adults with primary Sjögren's disease, achieved the primary endpoint of improving disease activity compared to placebo.

Current Price	$9.02
Prev Close	$8.88
Open	$9.41
Dividend Yield	N/A
50-Day Moving Average	$9.02
Beta	N/A
Avg. Volume	0.00
PE Ratio	N/A

52-Week High	$9.41
52-Week Low	$8.86
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

CNCR
Exchange Traded Concepts Trust - ETCT Loncar Cancer Immunotherapy ETF

Feed

News

Sentiment

Fundamentals

Info

Latest CNCR News

CNCRExchange Traded Concepts Trust - ETCT Loncar Cancer Immunotherapy ETF